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1 |  BACKGROUND
Nasopharyngeal carcinoma (NPC) is the most common can-
cer in South China and Southeast Asia; more than 80% of 
new NPC cases per year worldwide were reported from these 
areas,1,2 and it has a remarkably distinctive ethnic and geo-
graphic distribution, prevalent among Southern Chinese,3 
suggesting the existence of a genetic predisposition to NPC 
in these areas or populations in addition to other risk factors 
including Epstein- Barr virus (EBV) infection.
The human major histocompatibility complex (MHC) is 
located on the short arm of chromosome 6. It comprises more 
than 200 classical and nonclassical MHC genes that have 
long been believed to be involved in infection, inflamma-
tion, autoimmunity, and various cancers.4 Since the 1970s, 
numerous efforts have been made to reveal the association 
of the MHC with NPC, hypothesizing that some MHC loci 
or genes may play major roles in the genetic predisposition 
to NPC, probably either by modulating innate and adaptive 
immune responses or as genetic markers of predisposition 
loci in close linkage.2,5 This was also strongly supported 
by two genomewide association studies (GWAS)6,7 and our 
recent association study.5 Despite the success of GWAS in 
identifying genetic variations, the variations in the genome 
have small effect sizes and only explain a modest fraction 
of the predicted genetic variance.8 And the single- nucleotide 
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Abstract
The major histocompatibility complex (MHC) is most closely associated with naso-
pharyngeal carcinoma (NPC), but the complexity of its genome structure has proven 
challenging for the discovery of causal MHC loci or genes. We conducted a targeted 
MHC sequencing in 40 Cantonese NPC patients followed by a two- stage replication 
in 1065 NPC cases and 2137 controls of Southern Chinese descendent. Quantitative 
RT- PCR analysis (qRT- PCR) was used to detect gene expression status in 108 NPC 
and 43 noncancerous nasopharyngeal (NP) samples. Luciferase reporter assay and 
chromatin immunoprecipitation (ChIP) were used to assess the transcription factor 
binding site. We discovered that a novel SNP rs117565607_A at TRIM26 displayed 
the strongest association (OR = 1.909, Pcombined = 2.750 × 10−19). We also ob-
served that TRIM26 was significantly downregulated in NPC tissue samples with 
genotype AA/AT than TT. Immunohistochemistry (IHC) test also found the TRIM26 
protein expression in NPC tissue samples with the genotype AA/AT was lower than 
TT. According to computational prediction, rs117565607 locus was a binding site for 
the transcription factor Yin Yang 1 (YY1). We observed that the luciferase activity of 
YY1 which is binding to the A allele of rs117565607 was suppressed. ChIP data 
showed that YY1 was binding with T not A allele. Significance analysis of microar-
ray suggested that TRIM26 downregulation was related to low immune response in 
NPC. We have identified a novel gene TRIM26 and a novel SNP rs117565607_A 
associated with NPC risk by regulating transcriptional process and established a new 
functional link between TRIM26 downregulation and low immune response in NPC.
K E Y W O R D S
immune response, nasopharyngeal carcinoma, single-nucleotide polymorphisms, targeted MHC 
sequencing, TRIM26
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polymorphisms (SNPs) that contribute to the bulk of the her-
itability tend to be spread across the genome and are not near 
genes with disease- specific functions.9
The MHC sequencing was first conducted in 1999,10 and 
its extended sequencing was next completed in 2004.11 The 
MHC region is one of the most complex regions in the human 
genome,12,13 owing to its extreme levels of polymorphism, 
interspersed repeats, and linkage disequilibrium, and it may 
complicate the genomewide association studies of causal loci 
or genes contributing to disease phenotypes in this region. It 
is still unclear, however, whether these findings reflect direct 
associations with human leukocyte antigen (HLA) genes and/
or to other genes in this gene- rich region.
Target- enrichment strategy is the method, in which ge-
nomic regions of particular interest are selectively captured 
before sequencing.14,15 This approach has proved to be a cost- 
effective solution for studying MHC region,16 particularly 
facilitating the population- based research. Consequently, in 
this study, we applied this approach to conduct a targeted 
MHC sequencing in 40 Cantonese NPC patients followed 
by a two- stage population- based replication to identify the 
causal MHC loci or genes contributing to NPC. Furthermore, 
we explored the molecular and functional implications of 
the most significantly associated SNP and its corresponding 
gene.
2 |  MATERIALS AND METHODS
2.1 | Study populations and Subjects
All NPC cases used for the targeted sequencing (40 cases), 
the stage I replication (297 cases and 611 controls), and the 
stage II replication (768 cases and 1526 controls) were re-
cruited from 4 hospitals (Jiangmen Hospital, Zhongshan 
Hospital, and Nanfang Hospital of Southern Medical 
University in Guangdong, China, as well as 303 Hospital 
of People’s Liberation Army of China in Nanning, China) 
in Guangdong and Guangxi provinces in South China from 
January 2004 to July 2008 (Table S12). All cases were newly 
diagnosed and histologically confirmed and had not received 
any therapy prior to sample collection. Healthy control sub-
jects were recruited from the physical examination centers 
at the same hospitals. They had neither a family/personal 
history of cancer nor other major illnesses (such as diabetes, 
SLE, and rheumatoid arthritis). The control subjects were 
also frequency- matched to cases by age, gender, geographic 
region, and ethnicity. Peripheral blood samples were col-
lected from all participants, and genomic DNA (gDNA) was 
extracted from peripheral blood mononuclear cells (PBMCs).
Additionally, 108 NPC specimens, 43 noncancerous naso-
pharyngeal (NP) samples, and their corresponding peripheral 
blood samples were collected from Zhongshan hospital (June 
2009- December 2012). NPC patients were pathologically 
diagnosed and had received no therapy prior to biopsy. 
Noncancerous subjects, suffering from noncancerous disor-
ders such as nasal obstruction and ear blockness, were en-
rolled from the same hospital and histologically confirmed. 
Total RNA and gDNA were extracted from both tissue and 
PBMC samples.
The study was approved by the Human Ethical Committee 
at Southern Medical University. Written informed consent 
was obtained from all participants.
2.2 | Target enrichment, sequencing, and 
data analysis
Before we get started, we also carefully designed a tar-
geted MHC massive paralleled sequencing approach, using 
more than 30 000 baits, based on the SureSelect platform 
(Agilent).17 This approach displayed a superior sequencing 
coverage (96.2%) of the MHC region than that (<30%) of a 
whole exome sequencing (SureSelect)18(Table S13), proving 
its higher robustness.
A total of 30 816 baits (probes, 120 mer) were gener-
ated from 4.42 Mb of MHC (Chr6:29.07- 33.49 Mb, hg18) 
via Agilent’s eArray design and then synthesized by Agilent 
Technologies. Repeat masker was used, and 2× tiling was se-
lected for probe coverage (Figure S1). Totally, 2.31 Mb of 
nonrepetitive MHC regions was targeted.
Targeted capture was carried out using SureSelect 
Reagent Kit (Agilent), according to the manufacturer’s pro-
tocols. Briefly, gDNA samples were randomly fragmented 
by Covaris S2 (Covaris Inc.) to approximately 200 bp, and 
adapters were ligated to both ends of the fragments. The 
adaptor- ligated templates were purified using Agencourt 
AMPure XP beads (Beckman Coulter). Product was am-
plified by ligation- mediated PCR, purified, and hybridized 
to the SureSelect baits for enrichment. After 24 hours, the 
hybridized fragments were washed, eluted, and further am-
plified by PCR with 10 cycles. The captured library was se-
quenced in Illumina GA IIx, according to the manufacturer’s 
protocols.
In read mapping and variant detection, the reference 
human genome used was UCSC assembly hg18 build (NCBI 
build 36.3), excluding random placed contigs and alternative 
haplotypes. The quality- filtered sequence reads were aligned 
to the human reference by SOAP2.2019 with a maximum of 
4 mismatches. The parameters were set as “- a - b - D - o - t - r1 
- n 4 - v 2”. The reads in the alignment that have identical start 
sites were considered as PCR duplicates and then removed.
The targeted sequencing data were compared with the 40 
Han Chinese in Beijing, China (CHB), sequences from the 
1000 Genomes Project. In fact, the CHB data we analyzed 
in our paper were from 1000 Genomes Pilot; therefore, only 
45 CHB subjects were available at that time. After quality 
control (excluding CHB samples with very low proportion 
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of overlapping SNPs with our target sequencing data), we 
only included 40 CHB subjects in our discovery stage. We 
next used maximum- likelihood method to discover candidate 
NPC- associated SNPs. This method is based on integrating 
over uncertainty in the data for each individual rather than 
first calling genotype. The likelihood ratio test (LRT) was 
utilized in the algorithm to qualify the significance of asso-
ciation between cases and controls.20 Fisher’s exact test was 
also performed for each variant based on the minor and major 
allele count in the aggregate data of cases and controls.
2.3 | The selection of candidate SNPs for 
replication
Single- nucleotide polymorphisms were annotated using an 
in- house pipeline and categorized into missense, splice site, 
untranslated region (UTR) and promoter SNPs that are likely 
to be more deleterious than synonymous and other noncod-
ing SNPs. Totally, 155 SNPs with potential functions were 
selected for further replication for showing evidence of as-
sociation; 81 SNPs with LRT ≥5 were firstly chosen, and 
additional 74 SNPs with Fisher’s exact test (P- value < .001) 
were then collected (Tables S4 and S5). Quality control cut-
offs were set at minor allele frequency (MAF) >1% in the 
population and call rate >95% in cases or controls. The sig-
nificant SNPs found at the stage I were further replicated in 
an additional population of Southern Chinese at the stage II.
2.4 | Genotyping and association analysis 
in the two- stage replication study
The selected SNPs were genotyped on Sequenom 
MassARRAY system.21 Briefly, gDNA samples were diluted 
to approximately 5- 10 ng/μL and amplified by multiplex PCR. 
PCR products were applied for locus- specific single- base 
extension reactions. Resulting products were desalted and 
transferred to a 384- element SpectroCHIP array for the allele 
detection on MALDI- TOF mass spectrometry (Sequenom).
The associations were analyzed by comparing MAF in 
cases with those of controls using PLINK 1.07 software,22 
using logistic regressions with an additive model to obtain 
the P values, odds ratios, and 95% confidence interval. Age 
and gender were included as covariates. All SNPs should 
pass the quality control (call rate > 95%, Hardy- Weinberg 
equilibrium P > .001, in the controls). The genetic statistical 
power was estimated for all genotyped SNPs using CaTS- 
Power Calculator software.23
2.5 | SNP genotyping of NPC tissues and 
patient- derived PBMCs
High- resolution DNA melting analysis (HRM)24 was per-
formed for SNP genotyping of NPC tissues and patient- derived 
PBMCs, according to the manufacturer’s instruction. Primer 
set (forward: GTTGAGTATGAGAGATGTGAGCAG; re-
verse: ATAAA AGGGCAGAACCATAGCAG) and probe 
(GACAAATTGTGTATGGGGAAGG GGAG) were de-
signed for rs117565607 (chr6_30280350). Primer asymme-
try ratio of 10:1 was used to gain sufficient double- stranded 
products for amplicon melting and enough single- stranded 
products for probe annealing. PCR was conducted in 96- 
well format with 20 μL volumes including 20 ng of gDNA 
using THUNDERBIRDTM Probe qPCR Mix (TOYOBO 
QPS- 101) on Mx3005P Stratagene. Melting acquisition was 
performed on the LightScannerTM (Idaho Technology, Salt 
Lake City, Utah) modified for high- resolution melting of LC 
Green Plus (Idaho). Melting curves were analyzed by the 
custom software written in LightScanner Call- IT (Idaho). 
Normalization and background subtraction were also per-
formed by fitting an exponential to the background surround-
ing the melting transitions of interest.
2.6 | Quantitative RT- PCR analysis (qRT- 
PCR)
Total RNA from each sample was reverse- transcribed to 
cDNA using a GoScript™ Reverse Transcription System 
(Promega). Real- time PCR was performed using Promega 
GoTaq® qPCR Master Mix (Promega) on Mx3005P 
Stratagene (Agilent). All data were normalized to ARF5 ex-
pression and further normalized to the control sample unless 
otherwise indicated. Primer sets were listed in Table S14.
2.7 | Chromatin immunoprecipitation 
(ChIP)
Chromatin immunoprecipitation was performed using EpiQuik 
tissue ChIP Kit (Epigentek, Farmingdale, NY) and YY1 an-
tibody (Santa Cruz; Protein A/G PLUS- Agarose was used), 
according to the manufacturer’s instruction, using NPC tis-
sue samples with different SNP genotypes and genders. After 
precipitation, primer set for rs117565607 (chr6_30280350) 
(forward: 5′- GTTGAGTATGAGAGATGTGAGCAG- 3′, 
reverse: 5′- ATAAAAGGGCAGAA CCATAGCAG- 3′) was 
used for enrichment by conventional PCR.
2.8 | Luciferase reporter assay
The PCR- amplified promoter fragment and the synthe-
sized SNP- T- or SNP- A- containing fragment (401 bp) of 
TRIM26 were cloned into luciferase reporter plasmid PGL3- 
basic vector using TOPO cloning kit (Invitrogen). The Yin 
Yang 1 (YY1) gene fragment was also amplified by PCR 
and cloned into PCDNA3.1 (+) vector. The cotransfec-
tions were performed using DharmaFECT Duo Transfection 
Reagent (Thermo Scientific) in 293T cells, according to 
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the manufacturer’s instruction. 293T cells were harvested 
48 hours after transfection, followed by the luciferase as-
says using the Dual- Luciferase® Reporter Assay System 
(Promega). Firefly and Renilla luciferase activities were 
measured as relative light units on luminometer (STRATEC 
Biomedical Systems, Birkenfeld, Germany). Transfection 
efficiency was standardized by the cotransfection of Renilla 
control vector. All assays were independently performed in 
triplicate.
2.9 | Immunohistochemistry (IHC)
Immunohistochemistry was conducted using standard tech-
niques as previously described,25 using a tripartite motif con-
taining 26 (TRIM26) rabbit anti- human polyclonal antibody 
(Novus Biologicals). Semiquantitative assessment of stain-
ing was carried out independently by two histopathologists.
2.10 | Microarray data analysis
Based on our previous gene expression profiling data of 23 
NPC and 8 NP tissues (GEO dataset GSE40290), we reor-
dered and selectively rearranged these samples into 3 sub-
groups (8 high- TRIM26- NPs, 7 high- TRIM26- NPCs, and 
7 low- TRIM26- NPCs), according to their TRIM26 expres-
sion levels (their mean sample/reference ratios ± SEM were 
2.01 ± 0.1058, 2.064 ± 0.0466, and 1.263 ± 0.0654, respec-
tively (P- values < .0001), when comparing high- TRIM26- 
NPCs or high- TRIM26- NPs with low- TRIM26- NPCs). 
Significance analysis of microarray (SAM)26 was used to an-
alyze gene expression difference by between high- TRIM26- 
NPCs and low- TRIM26- NPCs, and high- TRIM26- NPs and 
low- TRIM26- NPCs. The delta was set to 0.94 so that false 
discovery rate (FDR) was 5% for each group comparison. In 
addition, the gene expression signatures were analyzed by 
the knowledge- based annotation software, GenCLiP 2.0.27 In 
GenCLiP 2.0, P values were calculated by chi- square test, 
and the enrichment of gene functions was further clustered 
based on related genes, which is similar to DAVID soft-
ware.28 The heat map symbol provided a graphical view of 
gene- term relationships. The gene ontology (GO) analysis 
was also provided by GenCLiP 2.0.
2.11 | Cell isolation, culture, 
transfection, and interferon (IFN) treatment
Three NPC cell lines (5- 8F, CNE2, and Sune1) were ob-
tained from the Cancer Research Institute, Southern Medical 
University, Guangzhou, China, and cultured in RPMI- 1640 
(Corning) with 10% calf serum (Gibco) at 37°C in 5% CO2.
PBMCs from healthy donors were provided by Guangzhou 
blood bank center. PBMCs were purified from the buffy 
coat of heparinized whole- blood preparations by density 
centrifugation on low- endotoxin Ficoll- Hypaque (Pharmacia 
Biotech, Piscataway, NJ) and then cultured in RPMI- 1640 
(Corning) with 10% calf serum (Gibco) at 37°C in 5% CO2.
Natural killer (NK) cells were isolated from PBMCs using 
human CD56 microbeads MACS kit (Miltenyi Biotec), fol-
lowing the manufacturer’s protocol, and cultured in RPMI- 
1640 (Corning) with 10% calf serum (Gibco) at 37°C in 5% 
CO2.
SiRNA against TRIM26 (TRIM26- siRNA) was synthe-
sized by Genepharma (Shanghai, China). Cells (1 × 105) 
were seeded on 6- well plates in DMEM (Gibco) with 10% 
FBS (Gibco) 24 hours prior to transfection and then trans-
fected with siRNA at final concentrations of 0, 20, 50, and 
100 nmol/L, respectively, using Lipofectamine TM 2000 
(Invitrogen) in serum- free conditions. Five hours later, the 
medium was replaced with fresh DMEM with 10% FBS or 
10% FBS containing IFN- α2b.
The cells were treated with IFN- α2b at final concentra-
tions of 0, 125, 250, and 500 IU/mL, respectively.
2.12 | Western blotting
Cell lysate was prepared using RIPA buffer with protease 
inhibitors and then quantified using the BCA protein assay 
(BioTek, Beijing, China). Protein (20 μg) was loaded onto 
a 10% SDS- PAGE gel that was then transferred onto PVDF 
membrane and incubated with anti- TRIM26 (Novus), anti- 
NFKB2 (Proteintech), and anti- IRF7 (Proteintech), respec-
tively, at 4°C overnight in a blocker (3% nonfat dry milk/
BSA in TTBS), followed by incubation with HRP- conjugated 
secondary anti- rabbit (Proteintech). Protein was normalized 
with GAPDH (Abmart).
2.13 | Natural Killer (NK) cell 
cytotoxicity assay
NK cell cytotoxicity was evaluated by 3- (4,5- dimethylthiazo
l- 2- yl)- 2,5- diphenyltetrazolium bromide (MTT) assay using 
CNE2 as target cells. TRIM26- siRNA and control siRNA 
were used to treat these two types of cells.
Briefly, target cells were washed with PBS, resuspended 
with fresh 1640 culture medium, and seeded into a 96- well 
plate at a density of 5000 cells per well. Primary human 
NK cells were added at an effector- to- target (E:T) ratio of 
25:1 and incubated at 37°C in a humidified atmosphere of 
5% CO2. Two hundred μL of the same concentration of NK 
cells (E) and 200 μL of the same concentration of CNE2 
cells (T) were also incubated in different wells as blank 
and controls, respectively. After 24 hours, 20 μL of MTT 
solution (5 mg/mL) was added to each well and incubated 
for 4 hours. The supernatant was removed, and 200 μL 
of dimethyl sulfoxide (DMSO) was added to each well 
and agitated for 10 minutes to fully liquefy the crystals. 
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Absorbance was detected at 490 nm (630 nm as a reference 
wavelength) with an automatic ELISA reader. The result-
ing data are reported as the average optical density (OD) 
value. The percentage of NK cell cytotoxicity was calcu-
lated as follows: NKA% = (1- [ODexperimental – ODE]/
ODT) × 100%.
2.14 | Statistical analysis
Statistical analyses were performed by the SPSS 13.0 statisti-
cal software package (SPSS Inc., Chicago, IL). Student’s t test 
was used to determine the differences between groups for gene 
expression analyses and in vitro analyses. P- value of <.05 was 
used as the criterion of statistical significance if not particularly 
mentioned. All statistical tests were two- sided.
3 |  RESULTS
3.1 | Targeted MHC sequencing and the 
two- stage replication
The whole MHC region was firstly sequenced using genomic 
DNA extracted from peripheral blood mononuclear cells 
(PBMCs) of 40 Cantonese NPC patients (Figure S1). Mapping 
to the human reference genome, we achieved an average of 
92.3 Mb of mappable data per sample with a mean sequenc-
ing depth of 40.33- fold. The average sequence coverage was 
more than 95%, and 86.3% of coding and noncoding regions 
were covered at least tenfold (Table S1), subsequently using 
40 CHB (Han Chinese in Beijing, China) genome sequences 
from the 1000 Genomes Project as a control data. In order 
to exclude population heterogeneity, we had the principal 
component analysis (PCA) between 40 NPC samples and 40 
CHB samples in the MHC region. And the result of PCA 
indicated that there was no significant difference between 
them (Figure S2). And we conducted a sequencing- based as-
sociation analysis through LRT and the Fisher’s exact test 
and identified 5066 SNPs with significant evidence (P < .05, 
Figure 1A,B, Table S2). Notably, these variants include most 
of signals previously reported by two GWAS efforts6,7 and 
our previous study (Table S3),5 indicating the reliability of 
our results.
We next focused on missense, splice site, and regulatory 
SNPs that were more likely to have functional impacts than 
others. Totally, 155 SNPs including 81 SNPs with LRT ≥5 
and 74 SNPs with Fisher’s exact test P < .001 were cho-
sen as candidates for subsequent replications (Figure 1B, 
Tables S4 and S5). After quality control, 111 candidate 
SNPs were successfully genotyped in 297 NPC cases and 
611 healthy controls of Southern Chinese descent at the 
stage I replication (of the 44 excluded SNPs, 9 were re-
moved due to the repetitive sequence involved after extract-
ing their flanking sequences and the other 35 SNPs failed 
to pass the quality criterion: call rate >95% and Hardy- 
Weinberg equilibrium P > .001 in the control). For this 
part, we identified that 9 SNPs were significantly associ-
ated with NPC (Table S6) and they were further genotyped 
in another independent cohort of 768 NPC cases and 1526 
healthy controls of Southern Chinese descent at the stage II 
replication. It was discovered that 5 SNPs displayed consis-
tent association (Table 1). Then, we made a joint analysis 
of the combined stage I and stage II replication samples; 
these 5 SNPs showed more significant association, and two 
SNPs had the strongest association with NPC, surpassing 
the genomewide significance threshold after Bonferroni’s 
correction (Table 1). They are rs117565607 (novel- 1: 
chr6_30280350) at the 5′UTR of tripartite motif containing 
26 genes (TRIM26; OR = 1.91, Pcombined = 2.75 × 10−19) 
and rs1265053 at chromosome 6 open reading frame 15 
(C6orf15; OR = 0.60, Pcombined = 8.62 × 10−20; Table 1, 
Figure 1C).
PolyPhen shows that the impact of rs1265053 may be 
benign although it is probably related to the exonic splic-
ing of C6orf15. Both TFSEARCH and FastSNP predict that 
rs117565607 is probably involved in the transcriptional regu-
lation of TRIM26. TRIM26 is a member of the tripartite motif 
(TRIM) protein family composed of more than 70 members 
in human.29 In recent years, the TRIM protein family, such as 
TRIM3, TRIM16, TRIM28, and TRIM40, have been reported 
for their roles in cancers.30-33 However, to date, its role in 
tumor remains unclear. Therefore, in this study, to investigate 
into the relationship between TRIM26 and NPC, further func-
tional studies were carried out.
3.2 | The downexpression of TRIM26 in 
both NPC tissues and patient- derived PBMCs
To determine whether TRIM26 downregulation plays roles 
in NPC, we firstly test whether or not TRIM26 was down-
regulated in NPC. QRT- PCR was used to detect TRIM26 ex-
pression status in 108 NPC and 43 NP samples. As shown 
in Figure 2A, TRIM26 was significantly downexpressed in 
NPC specimens relative to NP samples, consistent with a 
set of gene expression data we previously submitted to GEO 
(GSE40290, Figure 2B). Moreover, we observed a reduced 
TRIM26 expression in patient- derived PBMCs that contain 
various immune cells (Figure 2A). These data suggested that 
TRIM26 was indeed downregulated in NPC, probably being 
involved in influencing immune response.
3.3 | The A allele of rs117565607 
responsible for TRIM26 downregulation
According to the computational prediction, we noted that 
rs117565607 locus was a binding site for the transcription 
factor YY1, which was encoded by YY1 gene located on the 
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chromosome 14q32.2 (Figure 3A, Figure S4). As a member 
of the GLI- Kruppel family of transcriptional factors, YY1 
functions as an oncogene in various types of cancers.34,35 
However, the role of YY1 in nasopharyngeal carcinoma re-
mains unknown.
To determine whether the SNP rs117565607 (A/T) was 
involved in the transcriptional regulation of TRIM26 in NPC, 
we firstly divided 108 clinical NPC samples into two groups 
according to the SNP genotype of rs117565607 and observed 
that TRIM26 was significantly downregulated in NPC tissue 
samples with genotype AA/AT (genotype based on sense 
strand of the sequence) than TT (Figure 3B). Similar results 
appeared in their corresponding PBMCs (Figure 3B), sug-
gesting that rs117565607_A was probably responsible for 
TRIM26 downregulation in NPC. The TRIM26 protein ex-
pression was also evaluated by IHC in representative NPC 
samples and found the TRIM26 protein expression in NPC 
tissue samples with the genotype AA/AT was lower than TT 
(Figure 3C).
In order to validate whether the different alleles (A or T) 
could influence the expression of TRIM26, we next did lu-
ciferase reporter assays using 293T cells of human origin. 
We designed antisense strand with luciferase reporter to 
introduce exogenous YY1 and observed that the luciferase 
F I G U R E  1  The targeted MHC sequencing and replication study. A, The study design outline. B, As pie charts indicated, 155 SNPs (81 SNPs 
with likelihood ratio test (LRT) >5 and 74 SNPs with Fisher’s exact test P- value < .001) with potential functions and suggestive associations were 
selected as candidates from 5066 significant SNPs identified by targeted MHC sequencing. C, Top- ranking SNPs with association evidence were 
replicated from 155 candidates in the two- stage replication study. The regional plot of association result was displayed, respectively, for the SNP 
with the most significant associations. Shown are P- values (−log10 scale) of the association tests for genotyped (diamonds) and sequenced or 
imputed (circles) SNPs. Genetic recombination rates, based on CHB (Han Chinese in Beijing, China) and JPT (Japanese in Tokyo, Japan) samples 
from the HapMap Project, are represented by light blue lines, and genes within the regions are depicted by dark blue arrows
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activity with TTTGGG which is binding to the A allele of 
rs117565607 was suppressed (Figure 3D). To further illus-
trate this result, we did ChIP assay using NPC tissue samples, 
and indeed, YY1 was binding with T (on the sense strand of 
the sequence) allele not the A allele (Figure 3E). These data 
indicated that when transcriptional factor YY1 was bind to the 
mutant of TRIM26 (rs117565607_A), the binding affinity of 
YY1 was reduced and the transcription activation ability was 
impaired; therefore, those subjects carrying this A allele were 
expected to have low expression of TRIM26.
3.4 | The relationship of TRIM26 
downregulation with low immune response 
in NPC
To explore the functional relevance of TRIM26 to NPC, we 
next applied the significance analysis of microarray (SAM) 
to do mining of NPC gene expression data (GSE40290). NPC 
samples were reclassified according to their relative TRIM26 
expression levels, and gene expression patterns were com-
pared between high- TRIM26- NPCs and low- TRIM26- NPCs, 
and we found 407 significantly differentially expressed 
genes in Figure 4A, Table S8. Then, we used GenCLiP pro-
grams to do data mining analysis of NPC gene expression 
data (GSE40290). The gene ontology (GO) analysis showed 
that genes related to the immune response, innate immune 
response, and antivirus response were significantly overrep-
resented in these downregulated genes; green represents the 
positive relationship between genes and terms, and black rep-
resents the unknown relationship (Figure 4B,C, Figure S4). 
These downexpressed genes were majorly involved in the 
multiple positive regulations (Table S9). To validate micro-
array data, we detected the expression of some important im-
mune genes such as NFKB2, IL-32, IRF7, CD38, and STAT1 
in NPC samples and patient- derived PBMCs with high- or 
low- TRIM26 expression level. We observed that most of 
these immune genes were indeed significantly downregu-
lated upon TRIM26 downregulation (Figure 4D,E). These 
data suggested that TRIM26 downregulation was related to 
low immune response in NPC.
Interferons have long been reported to play pleiotropic 
roles in cancer immunosurveillance and in the broader process 
of cancer immunoediting.36 Many TRIM genes are IFN in-
ducible and involved in IFN- mediated immune response.37,38 
To explore whether TRIM26 downregulation could reduce 
the effects of IFN- mediated immune response, we used type 
I IFN to treat NPC cells and PBMCs in which TRIM26 was 
silenced by siRNA. The IFN- induced immune gene expres-
sions were suppressed in NPC cell line CNE2 (Figure 5A) 
and normal PBMCs (Figure 5B) when TRIM26 was silenced. 
We have also obtained the consistency outcome in Western 
blotting (Figure 5C). Additionally, we also observed that si-
lencing of TRIM26 did attenuate immune gene expression TA
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in a dose- dependent manner (Figure S5A,B). Similar results 
were also observed in normal PBMCs (Figure S5E), sug-
gesting that silencing of TRIM26 was related to low immune 
response basally. We found that TRIM26 could be induced 
by IFN in a dose- dependent manner (Figure S5C,D) and 
similar results were also observed in normal PBMCs (Figure 
S5F). Collectively, these in vitro data further supported that 
TRIM26 downregulation was indeed related to low immune 
response in NPC.
3.5 | Downregulation of TRIM26 and 
attenuated cytotoxicity of NK
TRIM26 may influence immune response in both NPC cells 
and PBMCs, but we did not know whether downregulation of 
TRIM26 would weaken immune response of immune or cancer 
cells. So we used normal NK cell as a representative effector 
model cocultured with target cells (NPC CNE2 cells) to further 
verify it. We evaluated the cell- mediated killing of NK cells 
cocultured with CNE2 cells with the different treatments of 
TRIM26 by siRNA. We initially detected the cytotoxic activity 
of NK cells lacking TRIM26 expression by siRNA and observed 
that NK cell- mediated killing was relatively attenuated (Figure 
S6A). Next, we evaluated the cytotoxic activity of normal NK 
cells cocultured with CNE2 cells lacking TRIM26 expression. 
NK cell- mediated killing was relatively inhibited as well (Figure 
S6A). Furthermore, we did an in vitro experiment using cocul-
turing CNE2 cells and NK cells, both of which lacked TRIM26 
expression, and a substantial suppression of NK cell- mediated 
killing appeared (Figure S6B). These data demonstrated that 
TRIM26 downregulation could influence immune response by 
attenuating either immune cell function or the sensitization of 
cancer cells to immune defenses.
3.6 | Downregulation of TRIM26 and 
extensive gene expression dysregulations
We also extended our mining effort using GSE40290 data 
to compare gene expression pattern between high- or low- 
TRIM26- NPCs with NP samples. We found that 3711 genes 
were differentially expressed in low- TRIM26- NPCs (Figure 
S7B) and only 573 genes in high- TRIM26- NPCs compared 
with NP samples (Figure S7A). These genes were involved in 
multiple biologic processes in addition to immunity (Tables 
S10 and S11). It is tempting to speculate that lower TRIM26 
expression may be associated with a more extensive dys-
regulation of gene expressions involved in multiple signaling 
pathways, thus leading to high NPC susceptibility, although 
this still remains to be further elucidated.
4 |  DISCUSSION
Although GWAS has successfully identified numerous loci 
influencing disease risk so far, the mechanisms by which 
many significantly associated loci, particularly MHC loci, 
influence diseases are often unclear.39 Recently, the identifi-
cation of genes responsible for diseases has been facilitated 
with newly developed technologies, particularly the targeted 
capturing the genome of interest, followed by sequencing. 
Exome sequencing, emerging as a popular approach, has been 
widely applied to assess the associations of coding variations, 
both common and rare, with complex phenotypes.15,40,41 The 
present study first applied a targeted MHC sequencing to 
human cancer research followed by a two- stage population- 
based replication study, successfully identifying 5 SNPs with 
consistent associations and eventually pointing to a novel 
SNP rs117565607 at TRIM26, with the strongest associa-
tion (OR = 1.9090, Pcombined = 2.750 × 10−19) and potential 
function.
Interestingly, rs117565607 is monomorphic in other pop-
ulation except East Asian, and the frequency of A allele is 
higher in South China than in the north. We acknowledge 
the fact that the CHB and CHS (Southern Han Chinese) are 
separated as two subpopulations in Chinese Han in general 
and the allele frequency for the A allele of rs117565607 is 
F I G U R E  2  The downexpression of TRIM26 in both NPC 
tissues and patient- derived PBMCs. A, The expression of TRIM26 
was measured by qRT- PCR in NPC tissue samples, patient- derived 
PBMCs, and their control samples (***P < .001). B, TRIM26 
expression in NPC relative to normal controls based on the data mining 
of gene expression profiling of NPC derived from GEO (GSE40290) 
(ratio of sample to reference and two- sided nonparametric t- statistic 
test were used. t = 2.684, P = .0119). (N: NP sample; C: NPC sample)
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0.152 in CHS and 0.073 in CHB from 1000 Genomes Project 
Phase 3 (103 genotypes in CHB and 105 genotypes in CHS) 
and 0.165 in CHS and 0.062 in CHB from 1000 Genomes 
Project Phase 1 (97 genotypes in CHB and 100 genotypes 
in CHS). With respect to the difference between CHS and 
CHB, we replicated our results in two independent stages 
with 297 cases/611 controls and 768 cases/1526 controls, 
and the combined allele frequency in cases and controls was 
0.2009/0.1164 with a P value reaching the genomewide sig-
nificance (Table 1).
Furthermore, we calculated the linkage disequilibrium 
(LD) between the top SNP rs117565607 with the previously 
reported SNPs5-7 associated with NPC in MHC region in the 
1000 Genomes Project Phase 3 data. As shown in Table S7, 
very low correlations were identified between rs117560607 
with those SNPs, with the largest R2 of 0.0339 between 
rs117565607 and rs3129055 (near HLA-F gene), and SNP 
rs3129055 was found to have a significant association with 
NPC in the Taiwanese population.6 The lowest correlation 
was found between rs117565607 and rs28421666 with R2 of 
F I G U R E  3  The effect of SNP rs117565607 on TRIM26 downexpression. (A) As indicated, a transcription factor binding site for YY1 
is predicted to be produced at the 5′URT of TRIM26. (B) TRIM26 mRNA expression was assayed by qRT- PCR in clinical NPC tissues or 
corresponding PBMC samples with genotype AA/AT or TT of rs117565607 on the sense strand of the sequence. The mean and standard deviation 
(SD) are marked with black lines. Two- sided P- values were calculated by Student’s t test (***P < .001). (C) The TRIM26 protein expression was 
evaluated by IHC in representative NPC samples with AA, AT, or TT (left to right) on the sense strand of the sequence. Scale bar = 50 μm. (D) We 
designed antisense strand with luciferase reporter to introduce exogenous YY1 and observed that the luciferase activity with TTTGGG which is 
binding to the A allele of rs117565607 was suppressed. (A 401- bp fragment around rs117565607 in the 5′UTR of TRIM26 and promoter sequence 
were inserted into pGL3- basic vector. Luciferase assay was performed using 293T cells cotransfected with YY1- vector. Two independent- sample t 
test, ***P < .001.) (E) ChIP, using NPC tissue samples. DNA was immunoprecipitated with anti- YY1 or IgG (negative). PCR for genomic fragment 
(146 bp) around SNP rs117565607 was performed
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0.0002, which was near HLA-DQ/DR gene.7 These results 
suggested that the genetic effect of rs117565607 was inde-
pendent of the previously reported signals.
Therefore, we decided to do further investigation of this 
SNP rs117565607. Comprehensive functional and in vitro 
experiments revealed that this particular SNP was responsible 
for TRIM26 downregulation, which was related to abundant 
immune gene suppressions and extensive gene expression 
dysregulations, leading to high susceptibility to NPC.
YY1 is a member of the GLI- Kruppel family of transcrip-
tional factors, and in recent years, many studies have found 
that YY1 was abnormal expression in different human tumor 
tissues and participated in multiple signaling pathways which 
were associated with tumorigenesis.42,43 Our clinical data 
and functional analyses supported that genomic DNA frag-
ment containing the susceptible allele (A) of this particular 
SNP had a lower binding affinity to transcription factor YY1 
and a higher silencing efficacy against TRIM26 than that 
of the T allele, thereby downregulating TRIM26 expression 
(Figure 3). To our knowledge, rs117565607 has never been 
reported in NPC before and is not genetically linked to other 
NPC- associated variant sites previously reported.
Besides rs117565607, we observed additional 4 SNPs with 
consistent associations with NPC (Table 1). Rs1265053 at 
C6orf15 is less damaging based on the computational predic-
tion. However, the function of C6orf15 in humans is not clear. 
For other 3 SNPs, the P values are not small enough to provide 
convincing statistical support for the associations of these 3 
SNPs with NPC in the present study. This may be attributed to 
their relatively low MAFs in study population, so a larger- scale 
population is required to strengthen their associations.
TRIM26 is a member of the TRIM gene family and local-
izes to the MHC class I region on chromosome 6, and the pro-
tein mainly localizes to cytoplasmic bodies.44 However, the 
F I G U R E  4  The influence of TRIM26 downregulation on immune response in NPC. (A) As SAM (significance analysis of microarray) plot 
displayed, using data mining of gene expression profiling of NPC (GSE40290). (B) The significantly associated GO terms and associated gene 
heat map. (C) The most significantly associated GO terms (at least P < 1e- 05). Green represents the positive relationship between genes and terms. 
Black represents the unknown relationship. (D) Expression levels of TRIM26 and some immune genes in NPC tissue samples. E, Expression levels 
of TRIM26 and some immune genes in corresponding PBMC samples. *P < .05, **P < .01, ***P < .001
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detailed function of this protein is not well defined, and to 
date, its role in tumor remains unclear. In the past, Xiong et al45 
found that the expression of TRIM26 mRNA in nontumor NP 
epithelial tissues was significantly higher than that in NPC, 
suggesting that TRIM26 gene plays an important role in the 
development of nasopharyngeal carcinoma, which may be a 
tumor suppressor gene of nasopharyngeal carcinoma. In 2015, 
Wang et al46 found that TRIM26 was a novel tumor suppressor 
gene of hepatocellular carcinoma and its downregulation con-
tributes to worse prognosis. In the present study, we observed 
that TRIM26 was significantly downregulated in NPC and fur-
ther discovered the suppression of abundant immune genes in 
NPC upon TRIM26 downregulation, suggesting that TRIM26 
was involved in influencing immune response in NPC.
Nasopharyngeal carcinoma is an Epstein- Barr virus 
(EBV)- associated tumor, and most NPC patients have ev-
idence of infection by this virus.47 We used type I IFN to 
treat NPC cells and PBMCs to support it because IFNs have 
been best known for initiating an antiviral program of gene 
expression,48 although we did not directly discover the antivi-
ral effects of TRIM26 in this study. Impressively, our results 
showed that IFN could induce TRIM26 expression along with 
highly expressed immune genes (Figure 5, Figure S6C,D), 
and in turn, the silencing of TRIM26 could attenuate IFN- 
mediated immune gene expression (Figure 5). These suggest 
a potential antiviral role of TRIM26 in NPC. It is worth noting 
that TRIM26 was downregulated in NPC cells in addition to 
PBMCs (Figure 3B). This may be a way in which cancer cells 
escape immune- mediated destruction under selection pres-
sure. It is well known that TRIMs have diverse expression 
patterns and have been found to be expressed in most tissues 
including cancer tissues, involving multiple processes. For 
example, TRIM28 expression in the normal adjacent tissues 
TRIM28 mRNA is significantly higher in breast cancer tis-
sues.49 And in this study, we found that the TRIM26 expres-
sion was higher with T allele at the SNP rs117565607 than 
with A allele (Figure 3B,C) and A allele was the risk for NPC 
in our study. To our knowledge, TRIM members have been 
rarely reported in cancer immune escape that is important for 
cancer development and progression, but some other immune 
genes are now reported to be involving it. For example, silenc-
ing of IRF7 pathways can promote immune escape of breast 
cancer cells, facilitating bone metastasis.50 Interestingly, si-
lencing of TRIM26 was found in our study to be able to atten-
uate the expression of IFN- mediated immune genes including 
IRF7 and NFKB2 (Figure 5, Figure S6). This suggests that the 
TRIM26 may be involved in cancer immune escape.
Natural killer cells are a main component of PBMCs51 and 
participate in innate immune responses against viruses and 
tumors.52-54 In the NK- mediated killing assays cocultured 
with NPC cells, we did observe that silencing of TRIM26 
not only directly attenuated NK cell cytotoxicity but also 
F I G U R E  5  The IFN- induced immune gene expressions were detected in NPC cell line CNE2 and normal PBMCs that were treated with 
TRIM26- siRNA. A, NPC cell line CNE2 by RT- QPCR; B, normal PBMCs by RT- QPCR. All qRT- PCR assays were performed in triplicate, and 
data shown are the mean and SD (*P < .05, **P < .01, ***P < .001). C, The effect of TRIM26 was confirmed by Western blotting.
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reduced the sensitization of NPC cells to NK- mediated kill-
ing (Figure S7). Particularly, an enhanced attenuation ap-
peared as both target cells and effector cells lacked TRIM26 
expression. This virtually mimics a low immune response 
in a cancer patient with low TRIM26 expression and fur-
ther supports the presence of a potential TRIM26- associated 
mechanism underlying immune escape of cancer cells.
In addition to low immune response, a more extensive 
dysregulation of gene expressions was observed in NPC pa-
tients with reduced TRIM26. Despite no support available 
from further clinical and experimental data, these results are 
heuristic for understanding the association of TRIM26 with 
NPC susceptibility; low immune response and extensively 
dysregulated gene expression owing to TRIM26 downregu-
lation probably confer a high susceptibility to NPC.
Our study was not without its limitations. Even we investi-
gated a new functional link between TRIM26 downregulation 
and low immune response in NPC. The mechanisms by which 
TRIM26 directly or indirectly regulates immune genes were 
not fully explored. The direct effect of TRIM26 on restricting 
EBV infection was also not investigated. Future studies are 
being planned. Moreover, the targeted MHC sequencing and 
replication studies should be planned in a larger study popu-
lation and different populations.
5 |  CONCLUSIONS
In conclusion, through a targeted MHC sequencing to cancer 
research and a population- based replication study as well as 
functional and molecular investigations, we have identified a 
novel SNP rs117565607 of TRIM26 gene and the A allele asso-
ciated with NPC risk that functions to decrease TRIM26 expres-
sion through YY1- mediated transcription and the establishment 
of a new functional link between TRIM26 downregulation and 
low immune response in NPC. This may help improve under-
standing of NPC susceptibility, develop new preventive strate-
gies in NPC endemic areas, and extend the functional spectrum 
of TRIM26 on other diseases in addition to NPC.
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